Daewoong Pharmaceutical Co., Ltd (KRX: 069620)

Market Cap	1.44T
Revenue (ttm)	1.42T
Net Income (ttm)	103.57B
Shares Out	11.51M
EPS (ttm)	9,001.68
PE Ratio	13.86
Forward PE	14.21
Dividend	600.00 (0.48%)
Ex-Dividend Date	Dec 27, 2024

Volume	24,314
Open	125,500
Previous Close	128,900
Day's Range	125,000 - 128,700
52-Week Range	100,100 - 164,400
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 10, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,727
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2023, Daewoong Pharmaceutical's revenue was 1.38 trillion, an increase of 7.44% compared to the previous year's 1.28 trillion. Earnings were 121.74 billion, an increase of 188.21%.